This website is intended for US healthcare professionals only.
VYEPTI permanent J-code (J3032) is now available. Learn more
FIND A VYEPTI-READY INFUSION CENTER IN YOUR AREA
You are about to leave the VYEPTI website for healthcare professionals
VYEPTI Dosing and Administration Video Coming Soon
By leaving this page, all selections will be lost. Do you want to continue?
Discover and download resources
files selected
Clear
Patient Discussion Guide
This guide includes helpful tips for discussing VYEPTI migraine prevention with your patients, including what they may expect from their IV treatment.
VYEPTI Infusion Checklist
Use this checklist to keep track of the complete VYEPTI dosing and administration process.
VYEPTI Antibody Science Review
Explore this brief overview of CGRP in migraine pathophysiology and the science behind therapeutic antibodies, including the purposeful design of VYEPTI.
Eptinezumab-jjmr—The Purposeful Design
Discover the intentional design features of eptinezumab-jjmr.
VYEPTI Dosing and Administration Video
Step-by-step instructions for the preparation and administration of VYEPTI.
Electra Patient Testimonial Video
Watch Electra discuss her experience with chronic migraine and VYEPTI.
VYEPTI: From Data to Patient Experience Video
Watch Dr Dawn C Buse, PhD, and Dr Andrew C Charles, MD, as they speak with Electra, a real migraine patient treated with VYEPTI. Learn about efficacy and safety data for VYEPTI and patient considerations when selecting treatment.
PROMISE-1 Study
Explore the pivotal trial results for eptinezumab-jjmr in episodic migraine.
PROMISE-2 Study
Explore the pivotal trial results for eptinezumab-jjmr in chronic migraine.
Patient Support Resources
See a variety of resources that can help support your VYEPTI patients.
Want updates when more resources become available?
You may also be interested in:
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
© 2021 Lundbeck. All rights reserved. VYEPTI, VYEPTI CONNECT, and VYEPTI GO are registered trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v6
This website is intended for US healthcare professionals only.
